Lancashire and South Cumbria
Formulary
Formulary
9 Nutrition and blood
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
09-02-01-01 Oral potassium
| Potassium Chloride Slow-K® |
|
Second Choice
|
| m/r tablets potassium 8mmol Avoid unless effervescent tablets or liquid preparations inappropriate |
|
| Potassium Chloride oral liquid |
|
Second Choice
|
Unlicensed potassium chloride oral solutions manufactured within the UK are available via Specials manufacturers, lead times vary. Care is needed to ensure selection of the most appropriate oral potassium supplement and delivery of the correct dosage.
This National Patient Safety Alert provides further background, clinical information and actions for providers. |
 CAS: UPDATE: Discontinuation of Kay-Cee-L (potassium chloride 375mg/ml) (potassium chloride 5mmol/5ml) syrup |
|
|
Links
- CAS: UPDATE: Discontinuation of Kay-Cee-L (potassium chloride 375mg/ml) (potassium chloride 5mmol/5ml) syrup
LSCMMG: PKU - Prescribing of Multivitamins & Phenylalanine-free amino acid substitutes for adults and children- NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
- NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
- NICE TA623: Patiromer for treating hyperkalaemia
- NICE TA623: Patiromer for treating hyperkalaemia